Technical Analysis for ACOR - Acorda Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
ACOR closed up 1.87 percent on Friday, October 20, 2017, on 74 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Oct 31
|See historical ACOR trend table...|
|Date||Alert Name||Type||% Chg|
|Oct 20||Spinning Top||Other||0.00%|
|Oct 19||Slingshot Bullish||Bullish Swing Setup||1.87%|
|Oct 17||Stochastic Reached Overbought||Other||2.06%|
|Oct 16||Doji - Bearish?||Reversal||4.41%|
|Oct 12||New Uptrend||Bullish||6.67%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACOR news...
|52 Week High||33.0|
|52 Week Low||13.6|
|200-Day Moving Average||21.2053|
|50-Day Moving Average||23.679|
|20-Day Moving Average||25.465|
|10-Day Moving Average||26.125|
|Average True Range||1.0212|
|Chandelier Exit (Long, 3 ATRs )||24.5364|
|Chandelier Exit (Short, 3 ATRs )||25.7636|
|Upper Bollinger Band||27.8911|
|Lower Bollinger Band||23.0389|
|Percent B (%b)||0.86|
|MACD Signal Line||0.8751|
|Market Cap||1.27 Billion|
|Num Shares||46.7 Million|
|Price-to-Earnings (P/E) Ratio||-28.94|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||28.85|
|Resistance 3 (R3)||28.80||28.20||28.58|
|Resistance 2 (R2)||28.20||27.78||28.23||28.48|
|Resistance 1 (R1)||27.70||27.52||27.95||27.75||28.39|
|Support 1 (S1)||26.60||26.68||26.85||26.65||26.01|
|Support 2 (S2)||26.00||26.42||26.03||25.92|
|Support 3 (S3)||25.50||26.00||25.83|
|Support 4 (S4)||25.55|